Media.Player

Method to Predict Treatment Response in Generalized Social Phobia

Detailed Technology Description

Inventors at UC San Diego have patented a method for optimizing therapeutic efficacy of treatment in a subject diagnosed with generalized social anxiety disorder. The method includes determining a subject's serotonin transporter gene promoter polymorphism genotype, correlating the subject's serotonin transporter gene promoter polymorphism genotype with a probability of being a positive responder or poor responder to therapy with a serotonin reuptake inhibitor, and selecting a drug for treatment based on the correlation. The method will assist physicians in making treatment decisions for individual patients with the disorder.

Supplementary Information

Patent Number: US8026059B2
Application Number: US2008279178A
Inventor: Stein, Murray B. | Gelernter, Joel
Priority Date: 15 Feb 2006
Priority Number: US8026059B2
Application Date: 22 Apr 2009
Publication Date: 27 Sep 2011
IPC Current: C12Q000168
US Class: 43500611 | 435006
Assignee Applicant: The Regents of the University of California
Title: Treatment response in generalized social phobia
Usefulness: Treatment response in generalized social phobia
Summary: The methods are useful for determining a response profile to treatment with a SRI in a subject diagnosed with generalized social anxiety disorder, determining whether to treat or continue treatment of a subject diagnosed with generalized social anxiety disorder with a serotonin reuptake inhibitor, and optimizing therapeutic efficacy of treatment in a subject diagnosed with generalized social anxiety disorder.
Novelty: Determining response profile to treatment with serotonin reuptake inhibitor (SRI) in a subject diagnosed with generalized social anxiety disorder by determining the subject's serotonin transporter gene promoter polymorphism genotype

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

8026059

Others

Intellectual Property Info

U.S. patent application (US-2009-0220971, “Treatment Response in Generalized Social Phobia” published 09/03/2009). Worldwide rights are available.

Related Materials

Stein MB, Seedat S, Gelernter J. Serotonin Transporter Gene Promoter Polymorphism Predicts SSRI Response in Generalized Social Anxiety Disorder. Psychopharmacology (Berl). 2006 Jul;187(1):68-72.

Tech ID/UC Case

19517/2006-021-0

Related Cases

2006-021-0

*Abstract

Social anxiety disorder, or social phobia, is a common, frequently disabling yet poorly understood disorder. Selective serotonin reuptake inhibitors (SSRIs) are most often used for treatment, yet 40 percent of the patients fail to derive benefit from the SSRIs. There is no method currently available for determining the likelihood of a successful response to SSRIs in individuals with this disease.

*IP Issue Date

Sep 27, 2011

*Principal Investigator

Name: Joel Gelernter

Department:

Name: Murray Stein

Department:

Country/Region

USA